RxDoctor Payments Data

Michael Guice, MD

General Practice · Los Angeles, CANPI 1215944285

Payments from drug & device makers

$52,960in general payments, 2019–2025

Across 30 payments — averaging $1765.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$51K
  • Amarin Pharma, Inc.$2K
  • GSK$500
  • Merck$171
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
  • Sanofi-aventis U.S. LLC$75
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$256100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$52,960 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$7,841
Medicare patients
16
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide77$94,673
EliquisApixaban14$17,348
Tresiba Flextouch U-200Insulin Degludec16$16,504
JanuviaSitagliptin Phosphate12$13,866
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$11,113
ZenpepLipase/Protease/Amylase13$10,899
Nifedipine ErNifedipine103$3,462
Celecoxib65$2,947
Albuterol Sulfate HfaAlbuterol Sulfate53$2,131
Potassium Chloride88$1,652
Labetalol Hcl47$1,618
Metformin Hcl101$1,146
Gabapentin76$1,075
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$936
Levothyroxine Sodium54$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50,532$17,34814 claims
MerckJanuvia$171$13,86612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →